IPHA Innate Pharma SA
Price Chart
Executive Summary
HC Wainwright upgraded IPHA to Buy from Neutral with a new $5 price target, representing 265% upside from the current $1.37. The firm has a 54% accuracy rate on 13 calls, above the sector average. Consensus remains bullish with 88% Buy or Strong Buy ratings (7 of 8 analysts), though the mean PT of $6 implies 338% upside, well above HC Wainwright’s $5 target. Recent EPS revisions are mixed: 1 down revision in the last 30 days for current quarter, but 2 upward revisions for +1y EPS. Institutional activity is split: CITADEL increased and then trimmed positions, while UBS repeatedly trimmed. No earnings date is scheduled within 30 days. This upgrade aligns with consensus but follows a prior downgrade by HC Wainwright in September 2025, making it a reversal rather than new conviction.
Impact Score
Consensus & Targets
Of 8 analysts covering IPHA, 71% rate it Buy (5) or Strong Buy (2), 14% Hold (1), and 0% Sell. There are no Sell or Strong Sell ratings. The consensus direction is firmly bullish, with the majority of analysts maintaining positive stances despite recent volatility in price targets and ratings.
The current share price is $1.37. The consensus mean price target is $6.00 (median: $6.50, high: $8, low: $3), implying 338% upside to the mean. HC Wainwright’s $5 target is below the mean and median, ranking in the 25th percentile of published targets. BTIG maintains the highest target at $8.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-07 | HC Wainwright & Co. | reiterate | Buy | — |
| 2025-10-29 | HC Wainwright & Co. | upgrade | Buy | $5.00 |
| 2025-10-29 | BTIG | reiterate | Buy | $8.00 |
| 2025-09-18 | Leerink Partners | downgrade | Market Perform | $2.00 |
| 2025-09-18 | HC Wainwright & Co. | downgrade | Neutral | — |
| 2025-04-24 | HC Wainwright & Co. | reiterate | Buy | $11.00 |
| 2025-03-28 | HC Wainwright & Co. | reiterate | Buy | $11.50 |
| 2025-02-06 | HC Wainwright & Co. | reiterate | Buy | $11.50 |
| 2025-01-17 | HC Wainwright & Co. | reiterate | Buy | $11.50 |
| 2024-12-09 | HC Wainwright & Co. | reiterate | Buy | $11.50 |
In the past 30 days, there have been 1 upgrade (HC Wainwright) and 1 downgrade (Leerink Partners). No other upgrades or downgrades occurred in the period. EPS revisions show slight improvement: 2 upward revisions in the last 7 days for +1y estimate, but 1 downward revision for the current quarter over 30 days. EPS estimates have trended lower over the past month for near-term periods.
Firm Track Record — HC Wainwright & Co.
HC Wainwright & Co. accuracy: 43% on 4605 calls | avg return: 2.5%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 1 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| HC Wainwright & Co. | 54% | 7/13 | 3.5% | above average |
HC Wainwright has a 54% accuracy rate on 13 rated calls for IPHA, above the sector average of 43% (2,002 of 4,605 calls correct across all firms). Among firms covering IPHA, HC Wainwright is the only one with a track record above average; others lack sufficient history for comparison. Their average return on rated stocks is 3.5%, above the 2.5% sector average.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $-0.09 | $-0.09 — $-0.09 | $7.9M | ↑0 ↓0 |
| 0y | $-0.55 | $-0.65 — $-0.45 | $31.1M | ↑2 ↓0 |
| 0q | $-0.16 | $-0.16 — $-0.16 | $2.3M | ↑0 ↓0 |
| +1y | $-0.63 | $-0.98 — $-0.40 | $64.8M | ↑2 ↓0 |
Cross-Platform Signals
Institutional activity shows mixed signals: CITADEL ADVISORS LLC first doubled its position (+104.7%, $43.2M) then trimmed by 44.3% ($21.9M). UBS Group AG made three trims totaling -58.3% of its position. No insider trades or congressional transactions are reported. Short interest data is unavailable. Institutional flows diverge from the analyst upgrade, showing distribution rather than accumulation.
Actionable Insight
HC Wainwright’s upgrade is a contrarian reversal after their own downgrade just one month prior, but comes from a high-accuracy firm. Given the lack of earnings catalysts in the near term and conflicting institutional flows, traders should await confirmation from volume or short-covering before positioning for a rally.
Documents Analyzed
Report based on filing metadata.
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 24, 2026
16d ago
|
ANALYST-UPGRADE
| $2.07 $1.89 | ▼ −8.70% | ▼ −7.68% | $1.76 (−14.98%) |
|
Apr 24, 2026
6w ago
|
ANALYST-UPGRADE
| $1.41 $1.97 | ▲ +39.72% | ▲ +35.69% | $1.76 (+24.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access